-
1
-
-
2442581507
-
Treating irritable bowel syndrome: Overview, perspective and future therapies
-
DOI 10.1038/sj.bjp.0705741
-
M Camilleri 2004 Treating irritable bowel syndrome: overview, perspective and future therapies Br J Pharmacol 141 1237 1248 1:CAS:528: DC%2BD2cXktFCgtLk%3D 10.1038/sj.bjp.0705741 15037521 (Pubitemid 38638813)
-
(2004)
British Journal of Pharmacology
, vol.141
, Issue.8
, pp. 1237-1248
-
-
Camilleri, M.1
-
2
-
-
33846347644
-
The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
-
DOI 10.1053/j.gastro.2006.11.002, PII S001650850602436X
-
MD Gershon J Tack 2007 The serotonin signaling system: from basic understanding to drug development for functional GI disorders Gastroenterology 132 397 414 1:CAS:528:DC%2BD2sXit1aqt78%3D 10.1053/j.gastro.2006.11.002 17241888 (Pubitemid 46127672)
-
(2007)
Gastroenterology
, vol.132
, Issue.1
, pp. 397-414
-
-
Gershon, M.D.1
Tack, J.2
-
3
-
-
70350567652
-
Current and novel therapeutic options for irritable bowel syndrome management
-
1:STN:280:DC%2BD1Mjktl2gtA%3D%3D 10.1016/j.dld.2009.07.009 19665953
-
M Camilleri V Andresen 2009 Current and novel therapeutic options for irritable bowel syndrome management Dig Liver Dis 41 854 862 1:STN:280:DC%2BD1Mjktl2gtA%3D%3D 10.1016/j.dld.2009.07.009 19665953
-
(2009)
Dig Liver Dis
, vol.41
, pp. 854-862
-
-
Camilleri, M.1
Andresen, V.2
-
4
-
-
71549121350
-
Review article: New receptor targets for medical therapy in irritable bowel syndrome
-
1:CAS:528:DC%2BC3cXnvFCltg%3D%3D 10.1111/j.1365-2036.2009.04153.x 19785622
-
M Camilleri 2010 Review article: new receptor targets for medical therapy in irritable bowel syndrome Aliment Pharmacol Ther 31 35 46 1:CAS:528:DC%2BC3cXnvFCltg%3D%3D 10.1111/j.1365-2036.2009.04153.x 19785622
-
(2010)
Aliment Pharmacol Ther
, vol.31
, pp. 35-46
-
-
Camilleri, M.1
-
5
-
-
44349130441
-
A placebo-controlled trial of prucalopride for severe chronic constipation
-
DOI 10.1056/NEJMoa0800670
-
M Camilleri R Kerstens A Rykx, et al. 2008 A placebo-controlled trial of prucalopride for severe chronic constipation N Engl J Med 358 2344 2354 1:CAS:528:DC%2BD1cXmsVKgsb0%3D 10.1056/NEJMoa0800670 18509121 This article describes the first pivotal phase 3 trial demonstrating that about 30% of patients with constipation achieve three or more SCBMs per week on prucalopride, compared to 12% on placebo (Pubitemid 351749158)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.22
, pp. 2344-2354
-
-
Camilleri, M.1
Kerstens, R.2
Rykx, A.3
Vandeplassche, L.4
-
6
-
-
58149084950
-
Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study
-
1:STN:280:DC%2BD1M%2FlvFajsQ%3D%3D 10.1111/j.1365-2036.2008.03884.x 19035970 This article describes one of the three pivotal phase 3 trials reporting on the efficacy and tolerability of prucalopride in patients with severe constipation
-
EM Quigley L Vandeplassche R Kerstens, et al. 2009 Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study Aliment Pharmacol Ther 29 315 328 1:STN:280: DC%2BD1M%2FlvFajsQ%3D%3D 10.1111/j.1365-2036.2008.03884.x 19035970 This article describes one of the three pivotal phase 3 trials reporting on the efficacy and tolerability of prucalopride in patients with severe constipation
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 315-328
-
-
Quigley, E.M.1
Vandeplassche, L.2
Kerstens, R.3
-
7
-
-
61649119045
-
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
-
1:CAS:528:DC%2BD1MXjsFGgt7o%3D 10.1136/gut.2008.162404 18987031 This article describes one of the three pivotal phase 3 trials showing that prucalopride improves bowel function, associated symptoms, and satisfaction in chronically constipated patients
-
J Tack M van Outryve G Beyens, et al. 2009 Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives Gut 58 357 365 1:CAS:528:DC%2BD1MXjsFGgt7o%3D 10.1136/gut.2008.162404 18987031 This article describes one of the three pivotal phase 3 trials showing that prucalopride improves bowel function, associated symptoms, and satisfaction in chronically constipated patients
-
(2009)
Gut
, vol.58
, pp. 357-365
-
-
Tack, J.1
Van Outryve, M.2
Beyens, G.3
-
8
-
-
0035121508
-
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
-
1:CAS:528:DC%2BD3MXhtlKltL4%3D 10.1053/gast.2001.21166 11159875
-
EP Bouras M Camilleri DD Burton, et al. 2001 Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder Gastroenterology 120 354 360 1:CAS:528: DC%2BD3MXhtlKltL4%3D 10.1053/gast.2001.21166 11159875
-
(2001)
Gastroenterology
, vol.120
, pp. 354-360
-
-
Bouras, E.P.1
Camilleri, M.2
Burton, D.D.3
-
9
-
-
0036109163
-
Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation
-
DOI 10.1046/j.1365-2036.2002.01210.x
-
CE Sloots AC Poen R Kerstens, et al. 2002 Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation Aliment Pharmacol Ther 16 759 767 1:CAS:528:DC%2BD38XjslCrsL8%3D 10.1046/j.1365-2036.2002.01210.x 11929394 (Pubitemid 34407524)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.4
, pp. 759-767
-
-
Sloots, C.E.J.1
Poen, A.C.2
Kerstens, R.3
Stevens, M.4
De Pauw, M.5
Van Oene, J.C.6
Meuwissen, S.G.M.7
Felt-Bersma, R.J.F.8
-
10
-
-
0036024222
-
Prucalopride, a systemic enterokinetic, for the treatment of constipation
-
1:CAS:528:DC%2BD38XntVCjs78%3D 10.1046/j.1365-2036.2002.01272.x 12144586
-
AV Emmanuel AJ Roy TJ Nicholls, et al. 2002 Prucalopride, a systemic enterokinetic, for the treatment of constipation Aliment Pharmacol Ther 16 1347 1356 1:CAS:528:DC%2BD38XntVCjs78%3D 10.1046/j.1365-2036.2002.01272.x 12144586
-
(2002)
Aliment Pharmacol Ther
, vol.16
, pp. 1347-1356
-
-
Emmanuel, A.V.1
Roy, A.J.2
Nicholls, T.J.3
-
11
-
-
0037540068
-
Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: Results of a double-blind, placebo-controlled clinical trial
-
DOI 10.1159/000070202
-
G Coremans R Kerstens M De Pauw, et al. 2003 Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial Digestion 67 82 89 1:CAS:528:DC%2BD3sXjsleitL4%3D 10.1159/000070202 12743445 (Pubitemid 36570307)
-
(2003)
Digestion
, vol.67
, Issue.1-2
, pp. 82-89
-
-
Coremans, G.1
Kerstens, R.2
De Pauw, M.3
Stevens, M.4
-
12
-
-
33845656047
-
4 receptor agonist, ATI-7505, in humans
-
DOI 10.1111/j.1365-2982.2006.00865.x
-
M Camilleri MI Vazquez-Roque D Burton, et al. 2007 Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans Neurogastroenterol Motil 19 30 38 1:CAS:528:DC%2BD2sXhtFOqu7bP 10.1111/j.1365-2982.2006.00865.x 17187586 This phase 2 trial demonstrated that ATI-7505 accelerates overall colonic transit, and tends to accelerate gastric emptying and loosen stool consistency in healthy subjects (Pubitemid 44952776)
-
(2007)
Neurogastroenterology and Motility
, vol.19
, Issue.1
, pp. 30-38
-
-
Camilleri, M.1
Vazquez-Roque, M.I.2
Burton, D.3
Ford, T.4
McKinzie, S.5
Zinsmeister, A.R.6
Druzgala, P.7
-
13
-
-
10744221896
-
Colonoscopy: Virtual, Optical, or Chromoscopic?
-
DOI 10.1053/j.gastro.2004.01.030
-
D Dennis M Palme I Irwin, et al. 2004 ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dog Gastroenterology 126 A641 10.1053/j.gastro.2004.01.030 (Pubitemid 38298309)
-
(2004)
Gastroenterology
, vol.126
, Issue.3
, pp. 641
-
-
Sandler, R.S.1
-
14
-
-
72449143707
-
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation
-
1:CAS:528:DC%2BC3cXhtlOhu7k%3D 19691492 This phase 2 trial demonstrated that velusetrag (TD-5108) accelerates intestinal and colonic transit after single dosing and accelerates gastric emptying after multiple dosing in healthy subjects and patients with constipation
-
ML Manini M Camilleri M Goldberg, et al. 2010 Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation Neurogastroenterol Motil 22 42 49 1:CAS:528:DC%2BC3cXhtlOhu7k%3D 19691492 This phase 2 trial demonstrated that velusetrag (TD-5108) accelerates intestinal and colonic transit after single dosing and accelerates gastric emptying after multiple dosing in healthy subjects and patients with constipation
-
(2010)
Neurogastroenterol Motil
, vol.22
, pp. 42-49
-
-
Manini, M.L.1
Camilleri, M.2
Goldberg, M.3
-
15
-
-
70350566903
-
4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation
-
4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation Gastroenterology 134 A545
-
(2008)
Gastroenterology
, vol.134
, pp. 545
-
-
Goldberg, M.R.1
Li, Y.P.2
Pitzer, K.3
-
16
-
-
72449201670
-
4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects
-
4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects Gastroenterology 132 A60
-
(2007)
Gastroenterology
, vol.132
, pp. 60
-
-
Goldberg, M.R.1
Wong, S.L.2
Ganju, J.3
-
17
-
-
33847365318
-
Pharmacological profile of ramosetron, a novel therapeutic agent for IBS
-
DOI 10.1007/s10787-006-1537-1
-
T Hirata T Funatsu Y Keto, et al. 2007 Pharmacological profile of ramosetron, a novel therapeutic agent for IBS Inflammopharmacol 15 5 9 1:CAS:528:DC%2BD2sXktFWgsbk%3D 10.1007/s10787-006-1537-1 (Pubitemid 46333875)
-
(2007)
Inflammopharmacology
, vol.15
, Issue.1
, pp. 5-9
-
-
Hirata, T.1
Funatsu, T.2
Keto, Y.3
Nakata, M.4
Sasamata, M.5
-
18
-
-
42249111897
-
3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: A comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer
-
DOI 10.1111/j.1365-2982.2007.01069.x
-
T Hirata Y Keto M Nakata, et al. 2008 Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer Neurogastroenterol Motil 20 557 565 1:CAS:528:DC%2BD1cXmslKlurg%3D 10.1111/j.1365-2982.2007.01069.x 18221252 (Pubitemid 351548641)
-
(2008)
Neurogastroenterology and Motility
, vol.20
, Issue.5
, pp. 557-565
-
-
Hirata, T.1
Keto, Y.2
Nakata, M.3
Takeuchi, A.4
Funatsu, T.5
Akuzawa, S.6
Sasamata, M.7
Miyata, K.8
-
19
-
-
48049093262
-
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome
-
1:CAS:528:DC%2BD1cXhtVejtrfN 10.1159/000150632 18667823
-
K Matsueda S Harasawa M Hongo, et al. 2008 A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome Digestion 77 225 235 1:CAS:528:DC%2BD1cXhtVejtrfN 10.1159/000150632 18667823
-
(2008)
Digestion
, vol.77
, pp. 225-235
-
-
Matsueda, K.1
Harasawa, S.2
Hongo, M.3
-
20
-
-
52149088774
-
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
-
1:CAS:528:DC%2BD1cXhtFCiu77I 10.1080/00365520802240255 18618371 This phase 3 trial demonstrated that ramosetron hydrochloride is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habit in patients with diarrhea-predominant irritable bowel syndrome
-
K Matsueda S Harasawa M Hongo, et al. 2008 A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome Scand J Gastroenterol 43 1202 1211 1:CAS:528:DC%2BD1cXhtFCiu77I 10.1080/00365520802240255 18618371 This phase 3 trial demonstrated that ramosetron hydrochloride is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habit in patients with diarrhea-predominant irritable bowel syndrome
-
(2008)
Scand J Gastroenterol
, vol.43
, pp. 1202-1211
-
-
Matsueda, K.1
Harasawa, S.2
Hongo, M.3
-
21
-
-
57649120166
-
Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients
-
1:CAS:528:DC%2BD1MXjtVykt7s%3D 10.1159/000185719 19092244
-
AW Mangel P Chaturvedi 2008 Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients Digestion 78 180 186 1:CAS:528:DC%2BD1MXjtVykt7s%3D 10.1159/000185719 19092244
-
(2008)
Digestion
, vol.78
, pp. 180-186
-
-
Mangel, A.W.1
Chaturvedi, P.2
-
22
-
-
33645812780
-
Effect of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle
-
R Ueno KJ Engelke H Osama 2005 Effect of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle Neurogastroenterol Motil 17 625
-
(2005)
Neurogastroenterol Motil
, vol.17
, pp. 625
-
-
Ueno, R.1
Engelke, K.J.2
Osama, H.3
-
23
-
-
33847009038
-
Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone
-
1:CAS:528:DC%2BD2sXjt1GltL4%3D 10.1152/ajpgi.00183.2006 17053162
-
AJ Moeser PK Nighot KJ Engelke, et al. 2007 Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone Am J Physiol Gastrointest Liver Physiol 292 G647 G656 1:CAS:528:DC%2BD2sXjt1GltL4%3D 10.1152/ajpgi.00183.2006 17053162
-
(2007)
Am J Physiol Gastrointest Liver Physiol
, vol.292
-
-
Moeser, A.J.1
Nighot, P.K.2
Engelke, K.J.3
-
24
-
-
33645837674
-
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
-
10.1152/ajpgi.00264.2005
-
M Camilleri AE Bharucha R Ueno, et al. 2006 Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers Am J Physiol Gastrointest Liver Physiol 290 942 947 10.1152/ajpgi.00264.2005
-
(2006)
Am J Physiol Gastrointest Liver Physiol
, vol.290
, pp. 942-947
-
-
Camilleri, M.1
Bharucha, A.E.2
Ueno, R.3
-
25
-
-
59449108998
-
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor function in healthy subjects
-
1:CAS:528:DC%2BD1MXitVaqt7c%3D 10.1152/ajpgi.90558.2008 19033530
-
S Sweetser IA Busciglio M Camilleri, et al. 2009 Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor function in healthy subjects Am J Physiol Gastrointest Liver Physiol 296 G295 G301 1:CAS:528:DC%2BD1MXitVaqt7c%3D 10.1152/ajpgi.90558.2008 19033530
-
(2009)
Am J Physiol Gastrointest Liver Physiol
, vol.296
-
-
Sweetser, S.1
Busciglio, I.A.2
Camilleri, M.3
-
26
-
-
40949131857
-
Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation
-
DOI 10.1111/j.1365-2036.2008.03629.x
-
JF Johanson DA Drossman R Panas, et al. 2008 Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation Aliment Pharmacol Ther 27 685 696 1:CAS:528:DC%2BD1cXls1Kjtbo%3D 10.1111/j.1365-2036. 2008.03629.x 18248656 (Pubitemid 351406304)
-
(2008)
Alimentary Pharmacology and Therapeutics
, vol.27
, Issue.8
, pp. 685-696
-
-
Johanson, J.F.1
Drossman, D.A.2
Panas, R.3
Wahle, A.4
Ueno, R.5
-
27
-
-
34548500315
-
Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome
-
DOI 10.1053/j.gastro.2007.06.067, PII S0016508507012991
-
V Andersen M Camilleri IA Busciglio, et al. 2007 Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome Gastroenterology 133 761 768 10.1053/j.gastro.2007.06.067 This phase 2a trial showed that linaclotide, 1000 μg once daily, significantly accelerated ascending colonic transit and altered bowel function (Pubitemid 47374145)
-
(2007)
Gastroenterology
, vol.133
, Issue.3
, pp. 761-768
-
-
Andresen, V.1
Camilleri, M.2
Busciglio, I.A.3
Grudell, A.4
Burton, D.5
McKinzie, S.6
Foxx-Orenstein, A.7
Kurtz, C.B.8
Sharma, V.9
Johnston, J.M.10
Currie, M.G.11
Zinsmeister, A.R.12
-
28
-
-
60749099506
-
Pilot study on the effect of linaclotide in patients with chronic constipation
-
1:CAS:528:DC%2BD1MXht1Shug%3D%3D 10.1038/ajg.2008.59 19098860
-
JM Johnston CB Kurtz DA Drossman, et al. 2009 Pilot study on the effect of linaclotide in patients with chronic constipation Am J Gastroenterol 104 125 132 1:CAS:528:DC%2BD1MXht1Shug%3D%3D 10.1038/ajg.2008.59 19098860
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 125-132
-
-
Johnston, J.M.1
Kurtz, C.B.2
Drossman, D.A.3
-
29
-
-
77249122338
-
Efficacy of linaclotide for patients with chronic constipation
-
1:CAS:528:DC%2BC3cXksVCrsb8%3D 10.1053/j.gastro.2009.12.050 20045700 This article reports a phase 2b trial of efficacy of linaclotide therapy with few adverse events in patients with chronic constipation
-
AJ Lembo CB Kurtz JE Macdougall, et al. 2010 Efficacy of linaclotide for patients with chronic constipation Gastroenterology 138 886 895.e1 1:CAS:528:DC%2BC3cXksVCrsb8%3D 10.1053/j.gastro.2009.12.050 20045700 This article reports a phase 2b trial of efficacy of linaclotide therapy with few adverse events in patients with chronic constipation
-
(2010)
Gastroenterology
, vol.138
-
-
Lembo, A.J.1
Kurtz, C.B.2
MacDougall, J.E.3
-
30
-
-
75349109261
-
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function
-
1:CAS:528:DC%2BC3cXjs1Grt7Y%3D 10.1016/j.cgh.2009.10.020 19879973 Two randomized, double-blind, placebo-controlled studies showed that sodium chenodeoxycholate in health and colesevelam in diarrhea-predominant irritable bowel syndrome have opposite effects on colonic transit and fecal parameters
-
ST Odunsi-Shiyanbade M Camilleri S McKinzie, et al. 2010 Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function Clin Gastroenterol Hepatol 8 159 165 1:CAS:528:DC%2BC3cXjs1Grt7Y%3D 10.1016/j.cgh.2009.10.020 19879973 Two randomized, double-blind, placebo-controlled studies showed that sodium chenodeoxycholate in health and colesevelam in diarrhea-predominant irritable bowel syndrome have opposite effects on colonic transit and fecal parameters
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 159-165
-
-
Odunsi-Shiyanbade, S.T.1
Camilleri, M.2
McKinzie, S.3
-
31
-
-
77957745464
-
Dose-related effects of chenodeoxycholate on gastrointestinal and colonic transit and bowel function in female patients with constipation-predominant irritable bowel syndrome
-
A Rao ST Odunsi M Camilleri, et al. 2010 Dose-related effects of chenodeoxycholate on gastrointestinal and colonic transit and bowel function in female patients with constipation-predominant irritable bowel syndrome Gastroenterology 138 S224
-
(2010)
Gastroenterology
, vol.138
, pp. 224
-
-
Rao, A.1
Odunsi, S.T.2
Camilleri, M.3
-
32
-
-
35448957983
-
Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics
-
DOI 10.1111/j.1572-0241.2007.01438.x
-
F Fernández-Bañares M Esteve A Salas, et al. 2007 Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics Am J Gastroenterol 102 2520 2528 10.1111/j.1572-0241.2007.01438. x 17680846 This prospective study assessed the presence of gluten-sensitive enteropathy, bile acid malabsorption, and sugar malabsorption in consecutive patients with chronic watery diarrhea of obscure origin fulfilling Rome II criteria (Pubitemid 47631771)
-
(2007)
American Journal of Gastroenterology
, vol.102
, Issue.11
, pp. 2520-2528
-
-
Fernandez-Banares, F.1
Esteve, M.2
Salas, A.3
Alsina, M.4
Farre, C.5
Gonzalez, C.6
Buxeda, M.7
Forne, M.8
Rosinach, M.9
Espinos, J.C.10
Maria Viver, J.11
-
33
-
-
67650480494
-
Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry
-
1:CAS:528:DC%2BD1MXpt1OltL8%3D 10.1111/j.1365-2982.2009.01288.x 19368662
-
M Camilleri A Nadeau WJ Tremaine, et al. 2009 Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry Neurogastroenterol Motil 21 734 739 1:CAS:528:DC%2BD1MXpt1OltL8%3D 10.1111/j.1365-2982.2009.01288.x 19368662
-
(2009)
Neurogastroenterol Motil
, vol.21
, pp. 734-739
-
-
Camilleri, M.1
Nadeau, A.2
Tremaine, W.J.3
-
34
-
-
0037781447
-
Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome
-
10.1111/j.1572-0241.2003.07542.x 12873581
-
SP Dunlop D Jenkins RC Spiller 2003 Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome Am J Gastroenterol 98 1578 1583 10.1111/j.1572-0241.2003.07542.x 12873581
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1578-1583
-
-
Dunlop, S.P.1
Jenkins, D.2
Spiller, R.C.3
-
35
-
-
15744374565
-
Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles
-
DOI 10.1053/j.gastro.2004.11.050
-
L O'Mahony J McCarthy P Kelly, et al. 2005 Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles Gastroenterology 128 541 551 10.1053/j.gastro.2004.11.050 15765388 (Pubitemid 40585355)
-
(2005)
Gastroenterology
, vol.128
, Issue.3
, pp. 541-551
-
-
O'Mahony, L.1
Mccarthy, J.2
Kelly, P.3
Hurley, G.4
Luo, F.5
Chen, K.6
O'Sullivan, G.C.7
Kiely, B.8
Collins, J.K.9
Shanahan, F.10
Quigley, E.M.M.11
-
36
-
-
71549163969
-
Clinical benefit in IBS after disodium cromoglycate involves mast cell-medicated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa
-
B Lobo M Vicario C Martinez, et al. 2009 Clinical benefit in IBS after disodium cromoglycate involves mast cell-medicated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa Gastroenterology 136 Suppl 1 156
-
(2009)
Gastroenterology
, vol.136
, Issue.SUPPL. 1
, pp. 156
-
-
Lobo, B.1
Vicario, M.2
Martinez, C.3
-
37
-
-
84871962585
-
Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients
-
Vienna, Austria OP397
-
Klooker TK, Koopman KE, Heide S, et al.: Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Proceedings of the United European Gastroenterology Federation (UEGF) Meeting. Vienna, Austria; 2008:OP397.
-
(2008)
Proceedings of the United European Gastroenterology Federation (UEGF) Meeting
-
-
Klooker, T.K.1
Koopman, K.E.2
Heide, S.3
-
38
-
-
67650523807
-
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proof-of-concept study
-
1:CAS:528:DC%2BD1MXhtVSnurzE 10.1111/j.1365-2036.2009.04041.x 19438846
-
R Corinaldesi V Stanghellini C Cremon, et al. 2009 Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study Aliment Pharmacol Ther 30 245 252 1:CAS:528:DC%2BD1MXhtVSnurzE 10.1111/j.1365-2036.2009.04041.x 19438846
-
(2009)
Aliment Pharmacol Ther
, vol.30
, pp. 245-252
-
-
Corinaldesi, R.1
Stanghellini, V.2
Cremon, C.3
-
39
-
-
0041343250
-
Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome
-
DOI 10.1046/j.1365-2036.2003.01640.x
-
SP Dunlop D Jenkins KR Neal, et al. 2003 Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome Aliment Pharmacol Ther 18 77 84 1:CAS:528:DC%2BD3sXmvFWgsLw%3D 10.1046/j.1365-2036.2003.01640.x 12848628 (Pubitemid 36897983)
-
(2003)
Alimentary Pharmacology and Therapeutics
, vol.18
, Issue.1
, pp. 77-84
-
-
Dunlop, S.P.1
Jenkins, D.2
Neal, K.R.3
Naesdal, J.4
Borgaonker, M.5
Collins, S.M.6
Spiller, R.C.7
-
40
-
-
0032924832
-
The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome
-
DOI 10.1016/S0016-5085(99)70226-X
-
M Delvaux D Louvel E Lagier, et al. 1999 The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome Gastroenterology 116 38 45 1:CAS:528:DyaK1MXlsl2gsg%3D%3D 10.1016/S0016-5085(99)70226-X 9869600 (Pubitemid 29013491)
-
(1999)
Gastroenterology
, vol.116
, Issue.1
, pp. 38-45
-
-
Delvaux, M.1
Louvel, D.2
Lagier, E.3
Scherrer, B.4
Abitbol, J.-L.5
Frexinos, J.6
-
41
-
-
0037378287
-
Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans
-
S Delgado-Aros HJ Chial M Camilleri, et al. 2003 Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans Am J Physiol Gastrointest Liver Physiol 284 558 566
-
(2003)
Am J Physiol Gastrointest Liver Physiol
, vol.284
, pp. 558-566
-
-
Delgado-Aros, S.1
Chial, H.J.2
Camilleri, M.3
-
42
-
-
45549083888
-
Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome
-
DOI 10.1111/j.1365-2036.2008.03730.x
-
AW Mangel JD Bornstein LR Hamm, et al. 2008 Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome Aliment Pharmacol Ther 28 239 249 1:CAS:528:DC%2BD1cXps1Gmt7k%3D 10.1111/j.1365-2036.2008.03730.x 18466359 (Pubitemid 351861967)
-
(2008)
Alimentary Pharmacology and Therapeutics
, vol.28
, Issue.2
, pp. 239-249
-
-
Mangel, A.W.1
Bornstein, J.D.2
Hamm, L.R.3
Buda, J.4
Wang, J.5
Irish, W.6
Urso, D.7
-
43
-
-
35548931920
-
Efficacy of On-Demand Asimadoline, a Peripheral κ-Opioid Agonist, in Females With Irritable Bowel Syndrome
-
DOI 10.1016/j.cgh.2007.07.011, PII S1542356507007148
-
LA Szarka M Camilleri D Burton, et al. 2007 Efficacy of on-demand asimadoline, a peripheral κ-opioid agonist, in females with irritable bowel syndrome Clin Gastroenterol Hepatol 5 1268 1275 1:CAS:528: DC%2BD2sXhsVektbzI 10.1016/j.cgh.2007.07.011 17900994 This randomized study compared the effect of the κ-opioid agonist, asimadoline, and placebo on episodes of abdominal pain in patients with IBS (Pubitemid 350019057)
-
(2007)
Clinical Gastroenterology and Hepatology
, vol.5
, Issue.11
, pp. 1268-1275
-
-
Szarka, L.A.1
Camilleri, M.2
Burton, D.3
Fox, J.C.4
McKinzie, S.5
Stanislav, T.6
Simonson, J.7
Sullivan, N.8
Zinsmeister, A.R.9
-
44
-
-
0030900827
-
Irritable bowel syndrome: A technical review for practice guideline development
-
DOI 10.1053/gast.1997.v112.agast972120
-
J Kanto L Kangas T Leppanen, et al. 1997 Tofizopam: a technical review for practice guideline development Gastroenterology 112 2120 2137 10.1053/gast.1997.v112.agast972120 (Pubitemid 27240803)
-
(1997)
Gastroenterology
, vol.112
, Issue.6
, pp. 2120-2137
-
-
Drossman, D.A.1
Whitehead, W.E.2
Camilleri, M.3
-
45
-
-
37149041916
-
Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
-
DOI 10.1111/j.1365-2036.2007.03566.x
-
SM Leventer K Raudibaugh CL Frissora, et al. 2008 Clinical trial: dextofisopam in the treatment of patients with diarrhea-predominant or alternating irritable bowel syndrome Aliment Pharmacol Ther 27 197 206 1:CAS:528:DC%2BD1cXitVKrsbY%3D 10.1111/j.1365-2036.2007.03566.x 17973974 (Pubitemid 350256611)
-
(2008)
Alimentary Pharmacology and Therapeutics
, vol.27
, Issue.2
, pp. 197-206
-
-
Leventer, S.M.1
Raudibaugh, K.2
Frissora, C.L.3
Kassem, N.4
Keogh, J.C.5
Phillips, J.6
Mangel, A.W.7
|